Top

International Journal of Mental Health and Addiction

26-12-2023 | Opioids | Brief Report

Opioid Agonist Maintenance Treatment Outcomes—The OPTIMUS International Consensus Towards Evidence-Based and Patient-Centred Care, an Interim Report

Authors: Lucas Wiessing, Prakashini Banka-Cullen, M. Gabriela Barbaglia, Vendula Belackova, Saed A. S. Belbaisi, Peter Blanken, Patrizia Carrieri, Catherine Comiskey, Daniel Dacosta-Sánchez, Geert Dom, Venus Fabricius, Hugo Faria, Liljana Ignjatova, Nemanja Inić, Britta Jacobsen, Jana D. Javakhishvili, Zuzana Kamendy, Máté Kapitány-Fövény, Anna Kiss, Evi Kyprianou, Kirsten Marchand, Tim Millar, Viktor Mravcik, Naser J. Y. Mustafa, Carlos Nordt, Markus Partanen, Mads Uffe Pedersen, Hanna Putkonen, Mariam Razmadze, Perrine Roux, Bernd Schulte, Paulo Seabra, Luis Sordo, Lisa Strada, Emilis Subata, Esmeralda Thoma, Marta Torrens, Alexander Y. Walley, Ioanna Yiasemi, for the OPTIMUS study group

Published in: International Journal of Mental Health and Addiction

Abstract

Non-medical opioid use is a major public health concern causing high mortality. While opioid agonist maintenance treatment (OMT) is a key life-saving intervention, there is (a) no international consensus on opioid treatment outcomes and (b) few opioid treatment outcome studies include key (public) health outcomes, such as overdose or HIV/hepatitis C. We report the rationale and study protocol for, and preliminary results of, an on-going international OMT outcomes consensus study that aims to address this double gap (n = 110 collaborating experts from 32 countries, plus a n = 477 Delphi evaluation panel from 26 of those countries: 58% male, 41% female; 47% OMT patients, 53% OMT professionals). We present a first draft of a patient interview guide (including a ‘clinical form’) to monitor OMT outcomes in six domains. The form appears to be well accepted and feasible in early testing. Through this, we aim to enhance the quality of and access to OMT and improve the survival, health, and quality of life of people who use opioids, while promoting non-stigmatising patient-physician relationships.

Available only for authorised users

American Hospital Association - Legislative Advisory. (2018). The support for patients and communities Act of 2018. Public Law, 115–271. https://www.aha.org/system/files/2018-10/181024-legislative-adv-patients-and-communities-act.pdf. Accessed 12 Dec 2023.

Allen, E. J., Palmateer, N. E., Hutchinson, S. J., Cameron, S., Goldberg, D. J., & Taylor, A. (2012). Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in Scotland. International Journal of Drug Policy, 23(5), 346–352.CrossRefPubMed

Anstice, S., Strike, C. J., & Brands, B. (2009). Supervised methadone consumption: client issues and stigma. Substance Use & Misuse, 44(6), 794–808.CrossRef

Bao, Y. P., Liu, Z. M., Epstein, D. H., Du, C., Shi, J., & Lu, L. (2009). A meta-analysis of retention in methadone maintenance by dose and dosing strategy. The American Journal of Drug and Alcohol Abuse, 35(1), 28–33.CrossRefPubMedPubMedCentral

Bøg, M., Filges, T., Brännström, L., Jørgensen, A. M. K., & Fredrikksson, M. K. (2017). 12-step programs for reducing illicit drug use. Campbell Systematic Reviews, 13(1), 1–149.CrossRef

Bogdanowicz, K. M., Stewart, R., Chang, C. K., Shetty, H., Khondoker, M., Day, E., ... & Strang, J. (2018). Excess overdose mortality immediately following transfer of patients and their care as well as after cessation of opioid substitution therapy. Addiction, 113(5), 946–951.

Brugal, M. T., Domingo-Salvany, A., Puig, R., Barrio, G., Garcia de Olalla, P., & De La Fuente, L. (2005). Evaluating the impact of methadone maintenance programmes on mortality due to overdose and aids in a cohort of heroin users in Spain. Addiction, 100(7), 981–989.CrossRefPubMed

Burki, T. (2019). Inquiry says that “UK drugs policy is failing.” The Lancet, 394(10209), 1605.CrossRef

Carrieri, P., Vilotitch, A., Nordmann, S., Lions, C., Michel, L., Mora, M., ... Methaville Study Group. (2017). Decrease in self-reported offences and incarceration rates during methadone treatment: A comparison between patients switching from buprenorphine to methadone and maintenance treatment incident users (ANRS-Methaville trial). International Journal of Drug Policy, 39, 86-91.

Deacon, R. M., Topp, L., Wand, H., Day, C. A., Rodgers, C., Haber, P. S., ... & Maher, L. (2012). Correlates of susceptibility to hepatitis B among people who inject drugs in Sydney, Australia. Journal of Urban Health, 89, 769–778.

Degenhardt, L., Grebely, J., Stone, J., Hickman, M., Vickerman, P., Marshall, B. D., ... & Larney, S. (2019). Global patterns of opioid use and dependence: Harms to populations, interventions, and future action. The Lancet, 394(10208), 1560–1579.

Eurasian Harm Reduction Association. (2020). Survey of client satisfaction with opioid maintenance therapy (OMT) services among patients of OMT programmes in Kyiv and the Kyiv Oblast region. Pilot study report. Vilnius: EHRA. https://harmreductioneurasia.org/wp-content/uploads/2020/06/Report-Eng06.03-1.pdf. Accessed 12 Dec 2023.

European Monitoring Centre for Drugs and Drug Addiction. (2023). European drug report 2023: trends and developments. Publications Office of the European Union. https://www.emcdda.europa.eu/publications/european-drug-report/2023_en

European Monitoring Centre for Drugs and Drug Addiction. (2012). Treatment demand indicator (TDI) standard protocol 3.0: Guidelines for reporting data on people entering drug treatment in European countries. Publications Office of the European Union. https://www.emcdda.europa.eu/system/files/media/publications/documents/675/EMCDDA-TDI-Protocol-3.0_392671.pdf. Accessed 12 Dec 2023.

European Monitoring Centre for Drugs and Drug Addiction. (2006). Annual Report 2006 - The state of the drugs problem in Europe (p 80). Publications Office of the European Union. https://www.emcdda.europa.eu/system/files/media/publications/documents/924/ar2006-en_69466.pdf. Accessed 12 Dec 2023.

European Monitoring Centre for Drugs and Drug Addiction. (2007). Annual Report 2007. The state of the drugs problem in Europe (p 70).Publications Office of the European Union. https://www.emcdda.europa.eu/system/files/media/publications/documents/446/TDAC07001ENC_84793.pdf. Accessed 12 Dec 2023.

Farré, M., Mas, A., Torrens, M., Moreno, V., & Camı́, J. (2002). Retention rate and illicit opioid use during methadone maintenance interventions: A meta-analysis. Drug and Alcohol Dependence, 65(3), 283–290.CrossRefPubMed

Feelemyer, J. P., Des Jarlais, D. C., Arasteh, K., Phillips, B. W., & Hagan, H. (2014). Changes in quality of life (WHOQOL-BREF) and addiction severity index (ASI) among participants in opioid substitution treatment (OST) in low and middle income countries: An international systematic review. Drug and Alcohol Dependence, 134, 251–258.CrossRefPubMed

Ferraro, C. F., Stewart, D. E., Grebely, J., Tran, L. T., Zhou, S., Puca, C., ... & French, C. E. (2021). Association between opioid agonist therapy use and HIV testing uptake among people who have recently injected drugs: A systematic review and meta‐analysis. Addiction, 116(7), 1664–1676.

Fordham A. (2022). 'Drug-free world' no more! Historic resolution at the UN spells end of consensus on drugs. International Drug Policy Consortium (IDCP). https://idpc.net/blog/2022/12/drug-free-world-no-more-historic-resolution-at-the-un-spells-end-of-consensus-on-drugs. Accessed 12 Dec 2023.

Frank, D. (2021). “That’s No Longer Tolerated”: Policing patients’ use of non-opioid substances in methadone maintenance treatment. Journal of Psychoactive Drugs, 53(1), 10–17.CrossRefPubMed

Fraser, H., Martin, N. K., Brummer-Korvenkontio, H., Carrieri, P., Dalgard, O., Dillon, J., ... & Hickman, M. (2018). Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. Journal of Hepatology, 68(3), 402–411.

Friedmann, P. D., & Schwartz, R. P. (2012). Just call it “treatment.” Addiction Science & Clinical Practice, 7, 1–3.CrossRef

Global Commission on Drug Policy. (2019). Classification of psychoactive substances: When science was left behind. http://www.globalcommissionondrugs.org/wp-content/uploads/2019/06/2019Report_EN_web.pdf. Accessed 12 Dec 2023.

Gowing, L. R., Hickman, M., & Degenhardt, L. (2013). Mitigating the risk of HIV infection with opioid substitution treatment. Bulletin of the World Health Organization, 91, 148–149.CrossRefPubMedPubMedCentral

Hamilton, L. K., Wheeler-Martin, K., Davis, C. S., Martins, S. S., Samples, H., & Cerdá, M. (2022). A modified Delphi process to identify experts’ perceptions of the most beneficial and harmful laws to reduce opioid-related harm. International Journal of Drug Policy, 108, 103809.CrossRefPubMed

Harm Reduction International. (2022). Global State of Harm Reduction 2022. Harm Reduction International. https://hri.global/wp-content/uploads/2022/11/HRI_GSHR-2022_Full-Report_Final-1.pdf. Accessed 12 Dec 2023.

Harris, J., & McElrath, K. (2012). Methadone as social control: Institutionalized stigma and the prospect of recovery. Qualitative Health Research, 22(6), 810–824.CrossRefPubMed

Interlandi J. (2023). One Year Inside a Radical New Approach to America’s Overdose Crisis. The New York Times. https://www.nytimes.com/2023/02/22/opinion/drug-crisis-addiction-harm-reduction.html. Accessed 12 Dec 2023.

James, S. L., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., ... & Briggs, A. M. (2018). Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. The Lancet, 392(10159), 1789–1858.

Jarvis, B. P., Holtyn, A. F., Subramaniam, S., Tompkins, D. A., Oga, E. A., Bigelow, G. E., & Silverman, K. (2018). Extended-release injectable naltrexone for opioid use disorder: A systematic review. Addiction, 113(7), 1188–1209.CrossRefPubMedPubMedCentral

Javakhishvili, J.D., Razmadze, M., Kutelia, L., Shengelia, N., Lejava, L. (2021). Survey of client satisfaction with opioid substitution program in Western Georgia (online). Eurasian Harm Reduction Association. Ilia State University. Vilnius, Lithuania, 2021. file:///Users/janajavakhishvili/Downloads/OST-Clients-Satisfaction-Survey-Report-EHAR-and-ILiauni-2021.pdf

Jünger, S., Payne, S. A., Brine, J., Radbruch, L., & Brearley, S. G. (2017). Guidance on Conducting and REporting DElphi Studies (CREDES) in palliative care: Recommendations based on a methodological systematic review. Palliative Medicine, 31(8), 684–706.CrossRefPubMed

Karnik, N. S., Marsden, J., McCluskey, C., Boley, R. A., Bradley, K. A., Campbell, C. I., ... & Wu, L. T. (2022). The opioid use disorder core outcomes set (OUD–COS) for treatment research: Findings from a Delphi consensus study. Addiction, 117(9), 2438–2447.

Katzman, J. G., Takeda, M. Y., Greenberg, N., Balasch, M. M., Alchbli, A., Katzman, W. G., ... & Bhatt, S. R. (2020). Association of take-home naloxone and opioid overdose reversals performed by patients in an opioid treatment program. JAMA Network Open, 3(2), e200117-e200117.

Lambdin, B., Cheng, B., Peter, T., Mbwambo, J., Apollo, T., Dunbar, M., ... & Volberding, P. (2015). Implementing implementation science: An approach for HIV prevention, care and treatment programs. Current HIV Research, 13(3), 244–246.

Larney, S., Peacock, A., Leung, J., Colledge, S., Hickman, M., Vickerman, P., ... & Degenhardt, L. (2017). Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: A systematic review. The Lancet Global Health, 5(12), e1208-e1220.

Levengood, T. W., Yoon, G. H., Davoust, M. J., Ogden, S. N., Marshall, B. D., Cahill, S. R., & Bazzi, A. R. (2021). Supervised injection facilities as harm reduction: A systematic review. American Journal of Preventive Medicine, 61(5), 738–749.CrossRefPubMedPubMedCentral

Lions, C., Carrieri, M. P., Michel, L., Mora, M., Marcellin, F., Morel, A., ... & Methaville Study Group. (2014). Predictors of non-prescribed opioid use after one year of methadone treatment: An attributable-risk approach (ANRS-Methaville trial). Drug and Alcohol Dependence, 135, 1-8.

MacArthur, G. J., Minozzi, S., Martin, N., Vickerman, P., Deren, S., Bruneau, J., ... & Hickman, M. (2012). Opiate substitution treatment and HIV transmission in people who inject drugs: Systematic review and meta-analysis. BMJ, 345.

Marchand, K., Foreman, J., MacDonald, S., Harrison, S., Schechter, M. T., & Oviedo-Joekes, E. (2020). Building healthcare provider relationships for patient-centered care: A qualitative study of the experiences of people receiving injectable opioid agonist treatment. Substance Abuse Treatment, Prevention, and Policy, 15, 1–9.CrossRef

Marsch, L. A. (1998). The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: A meta-analysis. Addiction, 93(4), 515–532.CrossRefPubMed

Marsden, J., Farrell, M., Bradbury, C., Dale-Perera, A., Eastwood, B., Roxburgh, M., & Taylor, S. (2008). Development of the treatment outcomes profile. Addiction, 103(9), 1450–1460.CrossRefPubMed

Mathers, B. M., Degenhardt, L., Ali, H., Wiessing, L., Hickman, M., Mattick, R. P., ... & Strathdee, S. A. (2010). HIV prevention, treatment, and care services for people who inject drugs: A systematic review of global, regional, and national coverage. The Lancet, 375(9719), 1014–1028.

Mathers, B. M., Degenhardt, L., Bucello, C., Lemon, J., Wiessing, L., & Hickman, M. (2013). Mortality among people who inject drugs: A systematic review and meta-analysis. Bulletin of the World Health Organization, 91, 102–123.CrossRefPubMedPubMedCentral

Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews, (2). https://doi.org/10.1002/14651858.CD002207.pub4

Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2009). Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database of Systematic Reviews, (3). https://doi.org/10.1002/14651858.CD002209.pub2

Mattson, C. L., Tanz, L. J., Quinn, K., Kariisa, M., Patel, P., & Davis, N. L. (2021). Trends and geographic patterns in drug and synthetic opioid overdose deaths—United States, 2013–2019. Morbidity and Mortality Weekly Report, 70(6), 202.CrossRefPubMedPubMedCentral

McAuley, A., Fraser, R., Glancy, M., Yeung, A., Jones, H. E., Vickerman, P., ... & Hutchinson, S. J. (2023). Mortality among individuals prescribed opioid-agonist therapy in Scotland, UK, 2011–20: A national retrospective cohort study. The Lancet Public Health.

Metzger, D. S., Woody, G. E., McLellan, A. T., O'Brien, C. P., Druley, P., Navaline, H., ... & Abrutyn, E. (1993). Human immunodeficiency virus seroconversion among intravenous drug users in-and out-of-treatment: An 18-month prospective follow-up. Journal of Acquired Immune Deficiency Syndromes, 6, 1049–1049.

Millar, T., & McAuley, A. (2017). EMCDDA assessment of drug-induced death data and contextual information in selected countries. https://www.emcdda.europa.eu/system/files/publications/4667/Assessment%20of%20drug-induced%20death%20data.pdf. Accessed 12 Dec 2023.

Minozzi, S., Amato, L., Vecchi, S., Davoli, M., Kirchmayer, U., & Verster, A. (2011). Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database of Systematic Reviews, (4). https://doi.org/10.1002/14651858.CD001333.pub4

Mohammadi, M., Kazeminia, M., Abdoli, N., Khaledipaveh, B., Shohaimi, S., Salari, N., & Hosseinian-Far, M. (2020). The effect of methadone on depression among addicts: A systematic review and meta-analysis. Health and Quality of Life Outcomes, 18(1), 1–12.CrossRef

Namchuk, A. B., Lucki, I., & Browne, C. A. (2022). Buprenorphine as a treatment for major depression and opioid use disorder. Advances in Drug and Alcohol Research, 2, 10254.CrossRefPubMedPubMedCentral

Nielsen, S., Tse, W. C., & Larance, B. (2022). Opioid agonist treatment for people who are dependent on pharmaceutical opioids. Cochrane Database of Systematic Reviews, (9). https://doi.org/10.1002/14651858.CD011117.pub3

Nordt, C., Wiessing, L., Kuijpers, W., Wisselink, J., Espelt, A., Brugal, M. T., ... & Herdener, M. (2018). Long-term opioid agonist treatment participation after first treatment entry is similar across 4 European regions but lower in Non-Nationals. European Addiction Research, 24(4), 173–183.

O’Connor, A. M., Cousins, G., Durand, L., Barry, J., & Boland, F. (2020). Retention of patients in opioid substitution treatment: A systematic review. PloS One, 15(5), e0232086.CrossRefPubMedPubMedCentral

Pierce, M., Bird, S. M., Hickman, M., Marsden, J., Dunn, G., Jones, A., & Millar, T. (2016). Impact of treatment for opioid dependence on fatal drug-related poisoning: A national cohort study in England. Addiction, 111(2), 298–308.CrossRefPubMed

Pitkänen, T., Kaskela, T., & Levola, J. (2020). Mortality of treatment-seeking men and women with alcohol, opioid or other substance use disorders–A register-based follow-up study. Addictive Behaviors, 105, 106330.CrossRefPubMed

Platt, L., Minozzi, S., Reed, J., Vickerman, P., Hagan, H., French, C., ... & Hickman, M. (2018). Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: Findings from a Cochrane Review and meta‐analysis. Addiction, 113(3), 545–563.

Radimecký, J. (2007). Rhetoric versus practice in Czech drug policy. Journal of Drug Issues, 37(1), 11–44.CrossRef

Razaghizad, A., Windle, S. B., Filion, K. B., Gore, G., Kudrina, I., Paraskevopoulos, E., ... & Eisenberg, M. J. (2021). The effect of overdose education and naloxone distribution: An umbrella review of systematic reviews. American Journal of Public Health, 111(8), e1-e12.

Rice, D., Corace, K., Wolfe, D., Esmaeilisaraji, L., Michaud, A., Grima, A., ... & Hutton, B. (2020). Evaluating comparative effectiveness of psychosocial interventions adjunctive to opioid agonist therapy for opioid use disorder: A systematic review with network meta-analyses. PLoS One, 15(12), e0244401.

Rosenberg, H., Grant, J., & Davis, A. K. (2020). Acceptance of non-abstinence as an outcome goal for individuals diagnosed with substance use disorders: A narrative review of published research. Journal of Studies on Alcohol and Drugs, 81(4), 405–415.CrossRefPubMed

Roux, P., Carrieri, M. P., Cohen, J., Ravaux, I., Poizot-Martin, I., Dellamonica, P., & Spire, B. (2009). Retention in opioid substitution treatment: A major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment. Clinical Infectious Diseases, 49(9), 1433–1440.CrossRefPubMed

Samet, J. H., & Fiellin, D. A. (2015). Opioid substitution therapy—Time to replace the term. The Lancet, 385(9977), 1508–1509.CrossRef

Santo, T., Clark, B., Hickman, M., Grebely, J., Campbell, G., Sordo, L., ... & Degenhardt, L. (2021). Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: A systematic review and meta-analysis. JAMA Psychiatry, 78(9), 979–993.

Schackman, B. R. (2010). Implementation science for the prevention and treatment of HIV/AIDS. Journal of Acquired Immune Deficiency Syndromes (1999), 55(Suppl 1), S27.CrossRefPubMed

Seabra, P. R. C., Amendoeira, J. J. P., & Sá, L. O. (2018). Testing nursing sensitive outcomes in out-patient drug addicts, with “Nursing Role Effectiveness Model.” Issues in Mental Health Nursing, 39(3), 200–207.CrossRefPubMed

Sharma, H. (2022). How short or long should be a questionnaire for any research? Researchers dilemma in deciding the appropriate questionnaire length. Saudi Journal of Anaesthesia, 16(1), 65.CrossRefPubMedPubMedCentral

Silverman, S. L. (2009). From randomized controlled trials to observational studies. The American Journal of Medicine, 122(2), 114–120.CrossRefPubMed

Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., ... & Pastor-Barriuso, R. (2017). Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ, 357.

Stirling, R., Nathan, S., & Ritter, A. (2023). Prioritizing measures to assess performance of drug treatment services: A Delphi process with funders, treatment providers and service-users. Addiction, 118(1), 119–127.CrossRefPubMed

Sun, H. M., Li, X. Y., Chow, E. P., Li, T., Xian, Y., Lu, Y. H., ... & Zhang, L. (2015). Methadone maintenance treatment programme reduces criminal activity and improves social well-being of drug users in China: A systematic review and meta-analysis. BMJ Open, 5(1), e005997.

The Global Fund. (2022). Technical brief. Harm reduction for people who use drugs: Priorities for investment and increased impact in HIV programming allocation period 2023–2025. The Global Fund. https://www.theglobalfund.org/media/1279/core_harmreduction_infonote_en.pdf?u=636850056300000000. Accessed 12 Dec 2023.

Torrens, M., Domingo-Salvany, A., Alonso, J., Castillo, C., & San, L. (1999). Methadone and quality of life. The Lancet, 353(9158), 1101.CrossRef

Torrens, M., Fonseca, F., Castillo, C., & Domingo-Salvany, A. (2013). Methadone maintenance treatment in Spain: The success of a harm reduction approach. Bulletin of the World Health Organization, 91, 136–141.CrossRefPubMedPubMedCentral

UNAIDS. (2021). Global AIDS strategy 2021–2026. End inequalities. End AIDS. [2022− 01− 03]. UNAIDS. https://www.unaids.org/en/Global-AIDS-Strategy-2021-2026. Accessed 12 Dec 2023.

UNODC. (2022). World drug report. United Nations New York, NY, 2. https://www.unodc.org/res/wdr2022/MS/WDR22_Booklet_2.pdf. Accessed 12 Dec 2023.

Van Draanen, J., Tsang, C., Mitra, S., Karamouzian, M., & Richardson, L. (2020). Socioeconomic marginalization and opioid-related overdose: a systematic review. Drug and Alcohol Dependence, 214, 108127.CrossRefPubMedPubMedCentral

Vos, T., Lim, S. S., Abbafati, C., Abbas, K. M., Abbasi, M., Abbasifard, M., ... & Bhutta, Z. A. (2020). Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. The Lancet, 396(10258), 1204–1222.

Wiessing, L. (2018). Report on workshop 4 monitoring treatment outcomes – A challenge worth the effort. TDI meeting / Treatment expert meeting, 3–4 October 2018. EMCDDA: Lisbon, 2018. https://drive.google.com/file/d/1rn8rPMB4EnFz18Y2c7Kxm2nLE6xPdb0W/view?usp=drive_link. Accessed 12 Dec 2023.

Wiessing, L. (2019). Expert meeting to start developing EMCDDA guidance for monitoring opioid substitution treatment outcomes in Europe. EMCDDA: Lisbon, 2019. https://drive.google.com/file/d/1vYaLJoLD2VoF2SHikL6x43wNodT33jMX/view?usp=drive_link. Accessed 12 Dec 2023.

Wiessing, L. G., Seguin-Devaux, C., & Merendeiro, C. S. (2021). Could the COVID-19 crisis help eradicate chronic homelessness? American Journal of Public Health, 111(1), 25.CrossRefPubMedPubMedCentral

Wiessing, L., Denis, B., & Guttormsson, U. et al., (2000). Estimating coverage of harm-reduction measures for injection drug users in Europe. Global Research Network on HIV Prevention in Drug-Using Populations- Third Annual Meeting Report. https://www.emcdda.europa.eu/system/files/attachments/14922/Wiessing_article_final.pdf. Accessed 12 Dec 2023.

Wiessing, L., Ferri, M., Běláčková, V., Carrieri, P., Friedman, S. R., Folch, C., ... & Griffiths, P. (2017). Monitoring quality and coverage of harm reduction services for people who use drugs: A consensus study. Harm Reduction Journal, 14, 1–14.

Wiessing, L., Ferri, M., Darke, S., Simon, R., & Griffiths, P. (2018). Large variation in measures used to assess outcomes of opioid dependence treatment: A systematic review of longitudinal observational studies. Drug and Alcohol Review, 37, S323–S338.CrossRefPubMed

Wiessing, L., Likatavičius, G., Klempová, D., Hedrich, D., Nardone, A., & Griffiths, P. (2009). Associations between availability and coverage of HIV-prevention measures and subsequent incidence of diagnosed HIV infection among injection drug users. American Journal of Public Health, 99(6), 1049–1052. https://ajph.aphapublications.org/doi/pdf/10.2105/AJPH.2008.141846. Accessed 12 Dec 2023.

Wild, T. C., Hammal, F., Hancock, M., Bartlett, N. T., Gladwin, K. K., Adams, D., ... & Hodgins, D. C. (2021). Forty-eight years of research on psychosocial interventions in the treatment of opioid use disorder: A scoping review. Drug and Alcohol Dependence, 218, 108434.

Woo, J., Bhalerao, A., Bawor, M., Bhatt, M., Dennis, B., Mouravska, N., ... & Samaan, Z. (2017). “Don’t judge a book by its cover”: A qualitative study of methadone patients’ experiences of stigma. Substance Abuse: Research and Treatment, 11, 1178221816685087.

World Health Organization, UNODC, UNAIDS. (2012). Technical Guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users- 2012 revision. https://www.who.int/publications/i/item/978924150437. Accessed 12 Dec 2023.

World Health Organization. (2005). Effectiveness of drug dependence treatment in prevention of HIV among injecting drug users. Evidence for action technical papers. https://apps.who.int/iris/bitstream/handle/10665/43259/9241593362-eng.pdf?sequence=1&isAllowed=y. Accessed 12 Dec 2023.

World Health Organization. (2020). International standards for the treatment of drug use disorders: Revised edition incorporating results of field-testing. https://www.ichom.org/portfolio/addiction/. Accessed 12 Dec 2023.

World Health Organization. (2023). Opioid overdose factsheet. https://www.who.int/news-room/fact-sheets/detail/opioid-overdose. Accessed 12 Dec 2023.

World Health Organization. (2009). Department of Mental Health, Substance Abuse, World Health Organization, International Narcotics Control Board, & United Nations Office on Drugs. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. World Health Organization. https://www.who.int/publications/i/item/9789241547543. Accessed 12 Dec 2023.

Title: Opioid Agonist Maintenance Treatment Outcomes—The OPTIMUS International Consensus Towards Evidence-Based and Patient-Centred Care, an Interim Report
Authors: Lucas Wiessing
Prakashini Banka-Cullen
M. Gabriela Barbaglia
Vendula Belackova
Saed A. S. Belbaisi
Peter Blanken
Patrizia Carrieri
Catherine Comiskey
Daniel Dacosta-Sánchez
Geert Dom
Venus Fabricius
Hugo Faria
Liljana Ignjatova
Nemanja Inić
Britta Jacobsen
Jana D. Javakhishvili
Zuzana Kamendy
Máté Kapitány-Fövény
Anna Kiss
Evi Kyprianou
Kirsten Marchand
Tim Millar
Viktor Mravcik
Naser J. Y. Mustafa
Carlos Nordt
Markus Partanen
Mads Uffe Pedersen
Hanna Putkonen
Mariam Razmadze
Perrine Roux
Bernd Schulte
Paulo Seabra
Luis Sordo
Lisa Strada
Emilis Subata
Esmeralda Thoma
Marta Torrens
Alexander Y. Walley
Ioanna Yiasemi
for the OPTIMUS study group
Publication date: 26-12-2023
Publisher: Springer US
Keywords: Opioids
Opioids
Published in: International Journal of Mental Health and Addiction
Print ISSN: 1557-1874
Electronic ISSN: 1557-1882
DOI: https://doi.org/10.1007/s11469-023-01213-9

EASD 2024

Springer Medicine

Opioid Agonist Maintenance Treatment Outcomes—The OPTIMUS International Consensus Towards Evidence-Based and Patient-Centred Care, an Interim Report

Abstract

EASD 2024

Springer Medicine

Abstract

Please log in to get access to this content